Investigation of Transcript Variant 6 of TPD52L2 as a Prognostic and Predictive Biomarker in Basal-Like MDA-MB-231 and MDA-MB-453 Cell Lines for Breast Cancer

Figure 1

Expression analysis of TPD52L2 in breast cancer. (a) TPD52L2 expression in cancer tissues based on TCGA dataset. (b) Comparative analysis of TPD52L2 expression between cancer tissues and paired adjacent normal tissues from the BRCA cohort of TCGA. The difference was not significant (paired -test). (c, d) TPD52L2 expression between cancer tissues and paired adjacent normal tissues in breast cancer patients with different PAM50 subtypes. (d) For BLBC patients, the difference between groups was significant (paired -test, ). (e) TPD52L2 expression between non-BLBC and BLBC patients from the BRCA cohort. The difference between groups was significant (Mann–Whitney test). (f, g) Comparative analysis of TPD52L2 expression in breast cancer patients from the BRCA cohort: (e) stages I, II, III, and IV and (f) T1, T2, T3, and T4. The differences between groups were significant (Mann–Whitney test, ).

(a)

(b)

(c)

(d)

(e)

(f)

(g)